Zacks Investment ResearchWed, 01 Apr 2026 13:10:28 GMTStrength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?RYTM+0.61%
The Motley FoolTue, 31 Mar 2026 20:00:00 GMTIs This Weight Loss Drug Stock a Buy After a New Approval?RYTM+0.61%
Investors Business DailyFri, 20 Mar 2026 13:23:55 GMTRhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'RYTM+0.61%
Seeking AlphaFri, 20 Mar 2026 07:32:19 GMTRhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity TranscriptRYTM+0.61%
Investors Business DailyTue, 17 Mar 2026 14:11:48 GMTRhythm Pharmaceuticals Misses The Beat In Obesity, But There's A CaveatRYTM+0.61%
Seeking AlphaTue, 17 Mar 2026 06:02:17 GMTRhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial TranscriptRYTM+0.61%
Seeking AlphaThu, 26 Feb 2026 20:08:20 GMTRhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call TranscriptRYTM+0.61%
Zacks Investment ResearchThu, 26 Feb 2026 15:56:04 GMTRhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue EstimatesRYTM+0.61%
BenzingaThu, 19 Feb 2026 17:42:46 GMTRhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity MarketRYTM+0.61%
Zacks Investment ResearchThu, 19 Feb 2026 16:00:33 GMTRhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?RYTM+0.61%
The Motley FoolMon, 02 Feb 2026 10:52:00 GMTThis High-Flying Growth Stock Is Hiding in Plain SightRYTM+0.61%